CORI Corium International, Inc.

3.83
+0  (0%)
Previous Close 3.83
Open 3.73
Price To book 30.16
Market Cap 86.19M
Shares 22,505,000
Volume 24,383
Short Ratio 13.11
Av. Daily Volume 40,681

SEC filingsSee all SEC filings

  1. DEF 14A - Other definitive proxy statements 17527842
  2. 8-K - Current report 17515762
  3. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 162061442
  4. 8-K - Current report 162010466
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161828270

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued 2013. Phase 3 top-line data released January 3, 2017 - poor data but partner Agile Therapeutics (AGRX) intends to reflile NDA 1H 2017.
Twirla
Contraceptive patch
Pilot bioequivalence initiated 4Q 2016. Data due 1H 2017. Pivotal trial to commence 2H 2017, with data mid-2018.
Corplex Donepezil
Alzheimer’s disease
Phase 2a data released July 2015
MicroCor PTH
Osteoporosis
Additional Phase 3 required following rejection of NDA. Trial is ongoing by partner Agile
AG200-15
Contraceptive

Latest News

  1. CORIUM INTERNATIONAL, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  2. ETFs with exposure to Corium International, Inc. : January 6, 2017
  3. CORIUM INTERNATIONAL, INC. Financials
  4. ETFs with exposure to Corium International, Inc. : December 23, 2016
  5. Corium International, Inc. :CORI-US: Earnings Analysis: 2016 By the Numbers : December 23, 2016
  6. CORIUM INTERNATIONAL, INC. Files SEC form 10-K, Annual Report
  7. ETFs with exposure to Corium International, Inc. : December 9, 2016
  8. Corium International, Inc. :CORI-US: Earnings Analysis: Q4, 2016 By the Numbers : November 28, 2016
  9. Edited Transcript of CORI earnings conference call or presentation 21-Nov-16 10:00pm GMT
  10. CORIUM INTERNATIONAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
  11. Corium Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Highlights
  12. Corium Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Highlights
  13. Q4 2016 Corium International Inc Earnings Release - After Market Close
  14. Aequus Prepares for Proof of Concept Clinical Study for Transdermal Anti-Nausea Diclegis Program
  15. Corium to Report Fourth Quarter and Year-end Fiscal Year 2016 Financial Results on Monday, November 21, 2016
  16. Corium to Report Fourth Quarter and Year-end Fiscal Year 2016 Financial Results on Monday, November 21, 2016
  17. Corium to Present at Dawson James Securities Growth Stock Conference
  18. Corium International (CORI) Jumps: Stock Moves Up 6.9%
  19. Corium Announces Streamlined Bioequivalence Development Path for Transdermal Corplex™ Memantine
  20. ETF’s with exposure to Corium International, Inc. : August 23, 2016

SEC Filings

  1. DEF 14A - Other definitive proxy statements 17527842
  2. 8-K - Current report 17515762
  3. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 162061442
  4. 8-K - Current report 162010466
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161828270
  6. 8-K - Current report 161807592
  7. 8-K - Current report 161715889
  8. CT ORDER - Confidential treatment order 161715485
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 161648295
  10. 8-K - Current report 161635876